Table 5.

Changes in Liver Histology in Ezetimibe- Versus Placebo-Treated Patients

	Ezetimibe (n = 17)			Placebo (n = 18)			Difference
	Baseline	Posttreatment	P Value	Baseline	Posttreatment	P Value	(P Value)
Steatosis
Median	2.0 (1.0)	1.0 (1.0)	0.2500	3.0 (1.0)	2.0 (1.0)	0.1133	0.0 (0.692)
N grade 0/1/2/3	0/7/6/4	0/5/3/2		0/2/5/11	0/4/8/6
Lobular inflammation
Median	1.0 (1.0)	2.0 (1.0)	0.2891	2.0 (1.0)	2.0 (1.0)	0.7266	0.0 (0.142)
N grade 0/1/2/3	0/10/7/0	0/7/9/1		0/5/13/0	0/7/11/0
Ballooning
Median	1.0 (1.0)	1.0 (2.0)	0.2734	1.5 (1.0)	1.0 (1.0)	0.2891	0.0 (0.552)
N grade 0/1/2	1/10/6	5/7/5		1/8/9	1/12/5
Fibrosis
Median	1.0 (2.0)	1.0 (3.0)	1.000	1.0 (3.0)	1.0 (2.0)	0.3750	0.0 (0.222)
N grade 0/1/2/3/4	5/6/2/3/1	7/3/2/5/0		6/5/1/5/1	4/6/2/5/1
NAFLD activity score
Median	5.0 (2.0)	4.0 (2.0)	0.2910	5.0 (1.0)	5.0 (2.0)	0.1372	0.0 (0.927)
		Ezetimibe n (%)			Placebo n (%)		Fisher's P value
2+ point improvement in NAS		5 (33.3%)			5 (27.8%)		1.000

Data are expressed as median (interquartile range) with P values from Wilcoxon's signed rank test or as n (%) with P values from Fisher's exact test.